Canada’s Drug Agency | Drugs, Health Technologies and Systems.

remdesivir

Details

Key Milestones2
Call for patient/clinician input openJanuary 08, 2024
Call for patient/clinician input closedMarch 04, 2024
Clarification:

- No patient input submission received

Submission receivedMarch 01, 2024
Submission acceptedMarch 18, 2024
Review initiatedMarch 19, 2024
Draft CADTH review report(s) provided to sponsor for commentMay 13, 2024
Deadline for sponsors commentsMay 23, 2024
CADTH review report(s) and responses to comments provided to sponsorJune 14, 2024
Expert committee meeting (initial)June 26, 2024
Draft recommendation issued to sponsorJuly 09, 2024
Draft recommendation posted for stakeholder feedbackJuly 18, 2024
End of feedback periodAugust 01, 2024
Final recommendation issued to sponsor and drug plansAugust 16, 2024
Final recommendation postedSeptember 04, 2024
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)August 30, 2024
CADTH review report(s) postedJanuary 08, 2025
Last Updated : January 8, 2025

capivasertib

Details

Key Milestones2
Call for patient/clinician input openJanuary 03, 2024
Call for patient/clinician input closedFebruary 26, 2024
Clarification:

- Patient input submission received from Breast Cancer Canada, Canadian Breast Cancer Network and Rethink Breast Cancer

Submission receivedFebruary 14, 2024
Submission acceptedFebruary 29, 2024
Review initiatedMarch 01, 2024
Draft CADTH review report(s) provided to sponsor for commentMay 27, 2024
Deadline for sponsors commentsJune 05, 2024
CADTH review report(s) and responses to comments provided to sponsorJune 27, 2024
Expert committee meeting (initial)July 10, 2024
Draft recommendation issued to sponsorJuly 23, 2024
Draft recommendation posted for stakeholder feedbackAugust 01, 2024
End of feedback periodAugust 16, 2024
Final recommendation issued to sponsor and drug plansAugust 30, 2024
Final recommendation postedSeptember 18, 2024
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)September 16, 2024
CADTH review report(s) postedJanuary 06, 2025
Last Updated : January 29, 2025

Nab-paclitaxel

Details

Key Milestones2
Call for patient/clinician input openJanuary 02, 2024
Call for patient/clinician input closedFebruary 26, 2024
Call for industry input openJanuary 02, 2024
Call for industry input closedFebruary 26, 2024
Submission receivedDecember 21, 2023
Expert committee meeting (initial)July 04, 2024
Draft recommendation posted for stakeholder feedbackAugust 01, 2024
End of feedback periodAugust 16, 2024
Final recommendation postedSeptember 24, 2024
Canada's Drug Agency review report(s) postedAugust 19, 2024
Last Updated : October 30, 2024

Mepolizumab

Details

Key Milestones2
Submission received19-Dec-23
Review initiated20-Dec-23
Expert committee meeting (initial)04-Jul-24
Draft recommendation posted for stakeholder feedback01-Aug-24
End of feedback period16-Aug-24
Clarification:

- Reconsideration: minor revisions requested by drug programs

- Request for reconsideration accepted

Final recommendation posted25-Nov-24
CADTH review report(s) posted10-Sep-24
Last Updated : February 10, 2025

cabotegravir

Details

Key Milestones2
Call for patient/clinician input openDecember 14, 2023
Call for patient/clinician input closedFebruary 12, 2024
Clarification:

- Patient input submission received from Peer Outreach Support Services & Education (POSSE), Africans in Partnership Against AIDS, Community-Based Research Centre, CATIE and HIV Network of Edmonton Society

Submission receivedFebruary 01, 2024
Submission acceptedFebruary 15, 2024
Review initiatedFebruary 16, 2024
Draft CADTH review report(s) provided to sponsor for commentMay 07, 2024
Deadline for sponsors commentsMay 16, 2024
CADTH review report(s) and responses to comments provided to sponsorJune 14, 2024
Expert committee meeting (initial)June 26, 2024
Draft recommendation issued to sponsorJuly 09, 2024
Draft recommendation posted for stakeholder feedbackJuly 18, 2024
End of feedback periodAugust 01, 2024
Final recommendation issued to sponsor and drug plansAugust 14, 2024
Final recommendation postedAugust 30, 2024
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)August 28, 2024
CADTH review report(s) postedJanuary 14, 2025
Last Updated : January 14, 2025

everolimus

Details

Key Milestones2
Call for patient/clinician input open14-Dec-23
Call for patient input open14-Dec-23
Call for patient input closed12-Feb-24
Call for patient/clinician input closed12-Feb-24
Call for industry input open14-Dec-23
Call for industry input closed12-Feb-24
Submission received12-Dec-23
Review initiated13-Dec-23
Expert committee meeting (initial)19-Sep-24
Draft recommendation posted for stakeholder feedback17-Oct-24
End of feedback period31-Oct-24
Final recommendation posted03-Dec-24
CADTH review report(s) posted07-Nov-24
Last Updated : February 10, 2025

pegcetacoplan

Details

Key Milestones2
Call for patient/clinician input open23-May-24
Clarification:

- CDA-AMC initially posted the call for patient from Dec 13 to Feb 12 . The pending submission was subsequently delayed and CDA-AMC re-posted the call for patient input when the revised filing date was received.

Call for patient/clinician input closed12-Jul-24
Clarification:

- Patient input submission received from Fighting Blindness Canada, The Canadian Council of the Blind, CNIB, International Federation on Ageing, Vision Loss Rehabilitation Canada, Association Québécoise de la dégénérescence maculaire

Submission received23-Jul-24
Submission accepted07-Aug-24
Review initiated08-Aug-24
Draft CADTH review report(s) provided to sponsor for comment01-Nov-24
Deadline for sponsors comments13-Nov-24
Clarification:

- Voluntarily withdrawn by the sponsor on 04 Feb 2025

Last Updated : March 11, 2025

etrasimod

Details

Key Milestones2
Call for patient/clinician input openDecember 08, 2023
Call for patient/clinician input closedFebruary 12, 2024
Clarification:

- Patient input submission received from Crohn's and Colitis Canada and Gastrointestinal Society

Submission receivedFebruary 05, 2024
Submission acceptedFebruary 20, 2024
Review initiatedFebruary 21, 2024
Draft CADTH review report(s) provided to sponsor for commentMay 14, 2024
Deadline for sponsors commentsMay 24, 2024
CADTH review report(s) and responses to comments provided to sponsorJune 14, 2024
Expert committee meeting (initial)June 26, 2024
Draft recommendation issued to sponsorJuly 10, 2024
Draft recommendation posted for stakeholder feedbackJuly 18, 2024
End of feedback periodAugust 01, 2024
Final recommendation issued to sponsor and drug plansAugust 14, 2024
Final recommendation postedAugust 30, 2024
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)August 28, 2024
CADTH review report(s) postedDecember 04, 2024
Last Updated : December 9, 2024

Renal cell carcinoma

Details

Review Type: Rapid

Provisional Funding Algorithm
Draft Report Posted: December 07, 2023
Stakeholder Feedback Deadline: December 14, 2023
Final Report Posted: 21 February , 2024
Last Updated : February 21, 2024

Nab-paclitaxel

Details

Key Milestones2
Call for patient/clinician input openNovember 29, 2023
Call for patient/clinician input closedJanuary 29, 2024
Call for industry input openNovember 29, 2023
Call for industry input closedJanuary 29, 2024
Submission receivedOctober 24, 2023
Review initiatedOctober 25, 2023
Expert committee meeting (initial)May 10, 2024
Draft recommendation posted for stakeholder feedbackJune 06, 2024
End of feedback periodJune 20, 2024
Final recommendation postedJuly 24, 2024
Canada's Drug Agency review report(s) postedJuly 16, 2024
Last Updated : October 30, 2024